₹2,634.00 ($27.35)

-74.80 (-2.76%)

BSE · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 44 · ₹200.4B mcap · 20M float · 0.067% daily turnover

Revenue

$21.9B +12.8% ▲

Gross Profit

$10.5B -7.8% ▼

Operating Income

$6.9B -22.1% ▼

Net Income

$6.4B +19.6% ▲

EPS (Diluted)

$84.11 +19.7% ▲

EBITDA

$8.8B +35.1% ▲

View Full Income Statement

Line Item	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2	FY2026 Q3	FY2026 Q4
Revenue	$4.9B	$5.0B	$5.1B	$5.3B	$5.4B	$6.0B
Cost of Revenue	$2.0B	$2.3B	$2.0B	$2.8B	$2.8B	$3.2B
Gross Profit	$3.0B	$2.7B	$3.1B	$2.6B	$2.6B	$2.8B
Gross Margin	60.4%	54.0%	61.7%	48.3%	47.6%	47.3%
R&D Expenses	$182M	$197M	$180M	$214M	$205M	$199M
SG&A Expenses	$468M	$466M	$432M	$659M	$676M	$784M
Operating Expenses	$649M	$663M	$611M	$873M	$882M	$983M
Operating Income	$2.3B	$2.1B	$2.5B	$1.7B	$1.7B	$1.9B
Operating Margin	47.2%	40.9%	49.8%	32.0%	31.4%	30.9%
Interest Expense	$2M	$2M	$2M	$2M	$2M	$4M
Income Before Tax	$1.8B	$1.8B	$1.8B	$2.0B	$2.0B	$2.1B
Tax Expense	$372M	$314M	$337M	$408M	$380M	$406M
Net Income	$1.4B	$1.4B	$1.5B	$1.5B	$1.6B	$1.7B
Net Margin	28.2%	28.3%	29.9%	28.9%	30.2%	28.3%
EPS (Diluted)	$18.19	$18.69	$20.03	$20.25	$21.51	$22.31
EBITDA	$1.6B	$1.7B	$1.8B	$2.2B	$2.2B	$2.3B
Shares Outstanding	76M	76M	76M	76M	76M	76M

CAPLIPOINT.BO BSE